<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00256685</url>
  </required_header>
  <id_info>
    <org_study_id>3151A2-319</org_study_id>
    <nct_id>NCT00256685</nct_id>
  </id_info>
  <brief_title>Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate
      (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with
      menopause, and also to assess the effects of DVS on sleep parameters and health outcomes
      indicators.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in average daily number of moderate &amp; severe hot flushes and average daily severity score at weeks 4 &amp; 12</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep, mood</measure>
  </secondary_outcome>
  <enrollment>568</enrollment>
  <condition>Menopause</condition>
  <condition>Hot Flashes</condition>
  <condition>Sleep Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DVS-233 SR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy, postmenopausal women who seek treatment for hot flushes

          -  Minimum of 7 moderate to severe hot flushes per day or 50 per week recorded for 7
             consecutive days during screening

          -  Body Mass Index (BMI) less than or equal to 40 kg/m2

        Other inclusions apply.

        Exclusion Criteria:

          -  Hypersensitivity to Venlafaxine

          -  History of seizure disorder

          -  History of myocardial infarction or unstable angina within 6 months

        Other exclusions apply.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2005</study_first_submitted>
  <study_first_submitted_qc>November 17, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2005</study_first_posted>
  <last_update_submitted>May 17, 2006</last_update_submitted>
  <last_update_submitted_qc>May 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2006</last_update_posted>
  <keyword>Menopause</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

